The Difference Between BLA and Non-BLA Skin Substitutes
In this edition of The JARALL Quarterly, we explore the critical differences between BLA (Biologics License Application) and non-BLA skin substitutes — and why it matters for your podiatry practice's wound care billing.
What You'll Learn
BLA vs. Non-BLA Classification: how the FDA categorizes skin substitutes and cellular tissue-based products (CTPs)
Billing and Reimbursement Impact: how product classification affects Medicare coverage and reimbursement rates
LCD Updates for 2026: the latest Local Coverage Determination changes and which products are covered, under MAC discretion, or non-covered
Product Selection Strategy: practical guidance on choosing the right products for your practice
Why This Matters
With the updated LCDs effective January 1, 2026, understanding the distinction between BLA and non-BLA products is more important than ever. Product classification directly impacts whether Medicare will reimburse for a given skin substitute — and choosing the wrong product can mean denied claims and lost revenue.
Watch the full webinar above for a detailed walkthrough of the current landscape and actionable steps for your practice.